Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Purpose To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. Methods Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations. Recommendations Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in > 10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not "must") be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended work-up for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 ( HER2/chromosome enumeration probe 17 [CEP17] ratio ≥ 2.0; average HER2 copy number < 4.0 signals per cell), ISH group 3 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 6.0 signals per cell), and ISH group 4 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 4.0 and < 6.0 signals per cell). The diagnostic approach includes more rigorous interpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to arrive at the most accurate HER2 status designation (positive or negative) based on combined interpretation of the ISH and IHC assays. The Expert Panel recommends that laboratories using single-probe ISH assays include concomitant IHC review as part of the interpretation of all single-probe ISH assay results. Find additional information at www.asco.org/breast-cancer-guidelines .

[1]  John M S Bartlett,et al.  Updated UK Recommendations for HER2 assessment in breast cancer , 2014, Journal of Clinical Pathology.

[2]  M. Bennett,et al.  Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection. , 2016, American journal of clinical pathology.

[3]  S. Bianchi,et al.  Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations , 2015, Pathology & Oncology Research.

[4]  K. Shojania,et al.  How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis , 2007, Annals of Internal Medicine.

[5]  A. Ashworth,et al.  Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis , 2009, The Journal of pathology.

[6]  S. Jaffer,et al.  The Impact of 2013 Updated ASCO/CAP HER2 Guidelines on the Diagnosis and Management of Invasive Breast Cancer: A Single-Center Study of 1739 Cases. , 2017, Clinical breast cancer.

[7]  C. Sung,et al.  Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective s , 2016, Breast Cancer Research and Treatment.

[8]  R. West,et al.  ‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study , 2017, Modern Pathology.

[9]  P. Diest,et al.  Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification , 2010, Breast Cancer Research and Treatment.

[10]  A. Luini,et al.  The clinical relevance of micropapillary carcinoma of the breast: a case–control study , 2013, Histopathology.

[11]  M. Dell'aquila,et al.  Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization , 2017, American journal of clinical pathology.

[12]  I. Reis,et al.  HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline , 2016, Breast Cancer Research and Treatment.

[13]  M. Dowsett,et al.  Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  K. Hess,et al.  Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study , 2017, Cancer.

[15]  P. Tan,et al.  Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer. , 2016, Archives of pathology & laboratory medicine.

[16]  C. Quinn,et al.  New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers , 2016, Virchows Archiv.

[17]  Mitch Dowsett,et al.  HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity , 2014, Modern Pathology.

[18]  S. Gunn,et al.  Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event , 2009, Modern Pathology.

[19]  A. Noske,et al.  Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience , 2015, PloS one.